Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis Noman ParachaAdriana ReyesAnder Urruticoechea Review Open access 25 February 2020 Pages: 597 - 609
Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer Thomas L. GonzalezMolly HancockJames M. Rae Preclinical study 17 February 2020 Pages: 611 - 622
Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer Thomas L. GonzalezMolly HancockJames M. Rae Correction 16 March 2020 Pages: 623 - 623
Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer Takahito MasudaHiroshi FujimotoMasayuki Ohtsuka Preclinical study 02 March 2020 Pages: 625 - 634
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer Kaitlyn J. AndreanoSuzanne E. WardellJohn D. Norris Preclinical study Open access 04 March 2020 Pages: 635 - 646
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy Denise A. YardleyNancy PeacockJohn D. Hainsworth Clinical trial 14 February 2020 Pages: 647 - 655
Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients Minsung KimHanna KimHee Jeong Kim Clinical Trial 19 February 2020 Pages: 657 - 663
The long-term effect of age on cardiovascular disease in patients with breast cancer who received chemotherapy Ye Won JeonHye Won BangGeeHee Kim Clinical Trial 25 February 2020 Pages: 665 - 674
Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial Irene E. G. van HellemondCarolien H. Smorenburgthe Dutch Breast Cancer Research Group (BOOG) Clinical trial Open access 02 March 2020 Pages: 675 - 685
Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer Madoka IwaseMasashi AndoHiroji Iwata Clinical trial 05 March 2020 Pages: 687 - 694
Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period Ciara C. O’SullivanSheeba IrshadKaren Lisa Smith Clinical trial 11 March 2020 Pages: 695 - 706
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy Theodore S. JennaroFang FangDaniel L. Hertz Clinical trial 12 March 2020 Pages: 707 - 714
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer Hiroshi IshiguroNorikazu MasudaMasakazu Toi Clinical trial Open access 13 March 2020 Pages: 715 - 724
De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study J. M. SimonsL. B. KoppertM. L. Smidt Clinical trial Open access 16 March 2020 Pages: 725 - 733
Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers S. P. CoronaM. BortulD. Generali Epidemiology 14 February 2020 Pages: 735 - 745
The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative Rachel YungRoberta M. RayKerryn W. Reding Epidemiology 15 February 2020 Pages: 747 - 757
The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer Lili ChenFangmeng FuChuan Wang Epidemiology 18 February 2020 Pages: 759 - 766
Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls Kathy PanRoberta M. RayRowan T. Chlebowski Epidemiology 19 February 2020 Pages: 767 - 775
Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases Laurence Lambert-CôtéAnne-Déborah BouhnikSophie Lauzier Epidemiology 21 February 2020 Pages: 777 - 790
A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women Elodia Rojas-LimaBrenda Gamboa-LoiraLizbeth López-Carrillo Epidemiology 22 February 2020 Pages: 791 - 800
Does persistent use of radiation in women > 70 years of age with early-stage breast cancer reflect tailored patient-centered care? Lauren J. TaylorJennifer S. SteimanHeather B. Neuman Epidemiology 03 March 2020 Pages: 801 - 807
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience Valerie E. CrolleyHusam MarashiJudy King Epidemiology Open access 13 March 2020 Pages: 809 - 817
Outcomes of primary endocrine therapy in elderly women with stage I–III breast cancer: a SEER database analysis Cai YuanZhigang XieKaren Daily Epidemiology 14 March 2020 Pages: 819 - 827
HER2-positivity in mucinous cancer might be related to accompanying infiltrating ductal carcinoma histology Kadri Altundag Letter to the Editor 11 March 2020 Pages: 829 - 829
Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer Ge MaBin ZhangJin Xu Letter to the Editor 14 March 2020 Pages: 831 - 832
Uterine ultrasound and endometrial biopsy in tamoxifen users P. NevenW. FroymanD. Timmerman Letter to the Editor 16 March 2020 Pages: 833 - 834